---
title: "Evaxion expands AI-Immunology platform into autoimmune disease drug concepts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298914375.md"
description: "Evaxion has expanded its AI-Immunology platform into autoimmune diseases, broadening R&D beyond vaccines. The company initiated experimental testing on two treatment concepts: a tolerogenic vaccine using T-cell epitopes and an autoantibody-binding antigen construct. Initial data is scheduled for presentation at PEGS Europe in Lisbon on November 18, 2026. The program aims to target disease drivers with high specificity for higher efficacy and fewer side effects compared to current therapies."
datetime: "2026-09-14T12:00:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298914375.md)
  - [en](https://longbridge.com/en/news/298914375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298914375.md)
generator: "portal-rs"
---

# Evaxion expands AI-Immunology platform into autoimmune disease drug concepts

-   Evaxion expanded its AI-Immunology platform into autoimmune diseases, broadening its R&D scope beyond vaccines. \* Experimental testing began on two treatment concepts: a tolerogenic vaccine using T-cell epitopes, and an autoantibody-binding antigen construct. \* Initial experimental data is scheduled for presentation at PEGS Europe in Lisbon on Nov. 18, 2026. \* The program targets disease drivers with high specificity, aiming for higher efficacy and fewer side effects than current symptom-focused therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800OMX\_\_\_\_\_CNEWS\_EN\_GNW1001262521\_en) on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)

## Related News & Research

- [Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma](https://longbridge.com/en/news/302259097.md)
- [Evaxion to Unveil New Phase 2 Immune Data for Personalized Cancer Vaccine EVX-01 in October and November 2026](https://longbridge.com/en/news/300805799.md)
- [CoreWeave AI Growth Comes With More Than $35 Billion in Debt](https://longbridge.com/en/news/303108283.md)
- [Micron Suffers a 99.8% Snub From Its Union, Exposing AI's Human Fault Line](https://longbridge.com/en/news/303110941.md)
- [Verizon CEO Says SpaceX May Be Years Away From Becoming America's 'Sixth' Wireless Competitor](https://longbridge.com/en/news/303109070.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**